1416 Results

People

  1. Motzer
    Motzer
  2. Vickers
    Vickers
  3. Hudis
    Hudis
  4. Norton
    Norton
  5. Saltz
    Saltz
  6. O'Reilly
    O'Reilly
  7. Mao
    Mao
  8. Morris
    Morris
  9. Seidman
    Seidman
  10. Kris
    Kris

Groups

  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)
  7. Hematologic Malignancies, Division of (169)
  8. Genitourinary Oncology Service (160)
  9. Center for Hematologic Malignancies (142)
  10. Gastrointestinal Oncology Service (126)
  1. "randomized controlled trial"
Formats
  1. Journal Article (1353)
  2. Review (19)
  3. Conference Paper (17)
  4. Editorial (9)
  5. Correspondence (5)
  6. Research Letter (5)
  7. Meeting Abstract (4)
  8. Guidelines (3)
  9. Book Section (1)
Groups
  1. Department of Medicine (753)
  2. Solid Tumor Oncology Division (541)
  3. Population Sciences Research Program (259)
  4. Survivorship Research (256)
  5. Surgery (244)
  6. Epidemiology and Biostatistics (187)

More Groups

People
  1. Robert Motzer (83)
  2. Andrew Vickers (48)
  3. Larry Norton (34)
  4. Clifford Hudis (33)
  5. Leonard Saltz (32)
  6. Eileen O'Reilly (25)

More People

Years
  1. 2025 (63)
  2. 2024 (165)
  3. 2023 (110)
  4. 2022 (81)
  5. 2021 (39)
  6. 2020 (51)

More Years

Publications
  1. Journal of Clinical Oncology (164)
  2. New England Journal of Medicine (65)
  3. Lancet Oncology (46)
  4. Cancer (42)
  5. Clinical Cancer Research (42)
  6. European Urology (26)

More Publications

Publishers
  1. Elsevier Inc. (187)
  2. American Society of Clinical Oncology (170)
  3. Elsevier Science, Inc. (138)
  4. Springer (79)
  5. Lippincott Williams & Wilkins (72)
  6. Wiley Blackwell (71)

More Publishers

Results (1416)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Incomplete cross-resistance between taxanes for advanced urothelial carcinoma: Implications for clinical practice and trial design
    Journal Article

    Sonpavde, G.; Pond, G. R.; Mullane, S.; Qu, A. Q.; di Lorenzo, G.; Federico, P.; Necchi, A.; Rosenberg, J. E.; Bellmunt, J.; Choueiri, T. K.
    Clinical Genitourinary Cancer (2015)

    Fulltext@MSK | Save
  • Five-year survival rates for treatment-naive patients with advanced melanoma who received ipilimumab plus dacarbazine in a phase III trial
    Journal Article

    Maio, M.; Grob, J. J.; Aamdal, S.; Bondarenko, I.; Robert, C.; Thomas, L.; Garbe, C.; Chiarion-Sileni, V.; Testori, A.; Chen, T. T.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Phase III open-label randomized study of cytarabine in combination with amonafide L-malate or daunorubicin as induction therapy for patients with secondary acute myeloid leukemia
    Journal Article

    Stone, R. M.; Mazzola, E.; Neuberg, D.; Allen, S. L.; Pigneux, A.; Stuart, R. K.; Wetzler, M.; Rizzieri, D.; Erba, H. P.; Damon, L.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • LEADER 2: Baseline calcitonin in 9340 people with type 2 diabetes enrolled in the Liraglutide Effect and Action in Diabetes: Evaluation of cardiovascular outcome Results (LEADER) trial: Preliminary observations
    Journal Article

    Daniels, G. H.; Hegedüs, L.; Marso, S. P.; Nauck, M. A.; Zinman, B.; Bergenstal, R. M.; Mann, J. F. E.; Derving Karsbøl, J.; Moses, A. C.; Buse, J. B.; more...
    Diabetes, Obesity and Metabolism (2015)

    Fulltext@MSK | Save
  • Bevacizumab for advanced cervical cancer: Patient-reported outcomes of a randomised, phase 3 trial (NRG Oncology-Gynecologic Oncology Group protocol 240)
    Journal Article

    Penson, R. T.; Huang, H. Q.; Wenzel, L. B.; Monk, B. J.; Stockman, S.; Long, H. J.; Ramondetta, L. M.; Landrum, L. M.; Oaknin, A.; Reid, T. J. A.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Optimizing the sequence of anti-EGFR-targeted therapy in EGFR-mutant lung cancer
    Journal Article

    Meador, C. B.; Jin, H.; de Stanchina, E.; Nebhan, C. A.; Pirazzoli, V.; Wang, L.; Lu, P.; Vuong, H.; Hutchinson, K. E.; Jia, P.; more...
    Molecular Cancer Therapeutics (2015)

    Fulltext@MSK | Save
  • Abiraterone acetate plus prednisone versus placebo plus prednisone in chemotherapy-naive men with metastatic castration-resistant prostate cancer (COU-AA-302): Final overall survival analysis of a randomised, double-blind, placebo-controlled phase 3 study
    Journal Article

    Ryan, C. J.; Smith, M. R.; Fizazi, K.; Saad, F.; Mulders, P. F. A.; Sternberg, C. N.; Miller, K.; Logothetis, C. J.; Shore, N. D.; Small, E. J.; more...
    Lancet Oncology (2015)

    Fulltext@MSK | Save
  • Impact of the addition of carboplatin and/or bevacizumab to neoadjuvant once-per-week paclitaxel followed by dose-dense doxorubicin and cyclophosphamide on pathologic complete response rates in stage II to III triple-negative breast cancer: CALGB 40603 (Alliance)
    Journal Article

    Sikov, W. M.; Berry, D. A.; Perou, C. M.; Singh, B.; Cirrincione, C. T.; Tolaney, S. M.; Kuzma, C. S.; Pluard, T. J.; Somlo, G.; Port, E. R.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Individual patient data analysis of progression-free survival versus overall survival as a first-line end point for metastatic colorectal cancer in modern randomized trials: Findings from the analysis and research in cancers of the digestive system database
    Journal Article

    Shi, Q.; De Gramont, A.; Grothey, A.; Zalcberg, J.; Chibaudel, B.; Schmoll, H. J.; Seymour, M. T.; Adams, R.; Saltz, L.; Goldberg, R. M.; more...
    Journal of Clinical Oncology (2015)

    Fulltext@MSK | Save
  • Highlights in lymphoma from the 2014 European Hematology Association Congress
    Journal Article

    Moskowitz, C. H.
    Clinical Advances in Hematology & Oncology (2014)

    Fulltext@MSK | Save